©2010 Ferrata Storti Foundation. This is an open-access paper ; Background Vγ9Vδ2 T lymphocytes are regarded as promising mediators of cancer immunotherapy due to their capacity to eliminate multiple experimental tumors, particularly within those of hematopoietic origin. However, Vγ9Vδ2 T-cell based lymphoma clinical trials have suffered from the lack of biomarkers that can be used as prognostic of therapeuti...
| Financiadores do RCAAP | |||||||
|
|
|
|
|
|
||